Accessibility Menu
MacroGenics Stock Quote

MacroGenics (NASDAQ: MGNX)

$2.02
(18.1%)
+0.31
Price as of October 21, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$2.02
Daily Change
(18.1%) +$0.31
Day's Range
$1.71 - $2.03
Previous Close
$2.02
Open
$1.71
Beta
1.46
Volume
859
Average Volume
767,082
Market Cap
127.7M
Market Cap / Employee
$2.02M
52wk Range
$0.99 - $5.1
Revenue
-
Gross Margin
0.82%
Dividend Yield
N/A
EPS
-$0.57
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

MacroGenics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
MGNX-47.67%-91.09%-38.35%-93%
S&P+15.06%+95.03%+14.29%+298%

MacroGenics Company Info

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$22.24M106.0%
Gross Profit$11.43M85.4%
Gross Margin51.38%-5.7%
Market Cap$76.34M-71.3%
Market Cap / Employee$0.22M0.0%
Employees3410.6%
Net Income-$36.25M34.9%
EBITDA-$34.85M38.2%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$130.69M55.7%
Accounts Receivable$12.53M102.4%
Inventory9.3731.8%

Liabilities

Q2 2025YOY Change
Long Term Debt$102.39M245.3%
Short Term Debt$5.12M16.3%

Ratios

Q2 2025YOY Change
Return On Assets-16.30%37.5%
Return On Invested Capital-47.52%2.8%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$47.70M-4.8%
Operating Free Cash Flow-$46.99M-5.6%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book3.571.700.690.96-61.48%
Price to Sales1.461.360.520.46-92.89%
Price to Tangible Book Value3.571.700.690.96-61.48%
Enterprise Value to EBITDA0.72-0.770.90-0.21-92.50%
Return on Equity-62.2%-49.9%-60.2%-69.7%-41.38%
Total Debt$34.10M$37.46M$37.47M$107.51M215.67%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.